Unilife in talks with customers about planned wind-down of syringe business

By Gareth Macdonald

- Last updated on GMT

iStock/Olivier Le Moal
iStock/Olivier Le Moal

Related tags U.s. securities and exchange commission

Unilfe has started discussing the wind-down of its prefilled syringe business with customers after deciding to focus on wearable drug delivery technologies.

The discussions were announced this week in a US Securities and Exchange Commission (SEC) filing​ in which Unilife also confirmed it will cease investment in its “other product platforms.”

A Unilife spokesman confirmed the plan, telling us that: “The other product platforms are the remainder of our portfolio that are not wearable injectors - prefilled syringes, ocular delivery, etc. We will only focus on wearable injectors going forward​.”

Hikma​ and Sanofi​ are among the firms that buy prefilled syringes from Unilife.

In the filing, Unilife said while it will no longer invest in non-wearables, it will retain associated intellectual property “in the event it becomes financially attractive for the company to further develop, customize, license or sell those products in the future​.”


Unilife announced its plan to focus on its wearables business in July​ as part of a wider cost reduction effort started in January.

The firm has wearable drug delivery technology deals with Amgen​, Sanofi​ and MedImmune​, the global biologics research and development arm of AstraZeneca.

In 2015​, AbbVie signed a strategic deal that granted it access to all of Unilife’s delivery technologies.

Unilife is due to hold a conference call on November 2 to update investors on its financial results and outlook.  

Related topics Drug Delivery Delivery technologies

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers